Personalized Medicine in Acromegaly: The ACROFAST Study
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae444 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Montserrat Marques-Pamies und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Hospital Municipal de Badalona, Badalona 08911, Spain. Hauptthemen laut MEDLINE: Acromegaly, Precision Medicine, Human Growth Hormone. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union-ERDF.
Abstract (Originalsprache)
Context
Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response.
Objective
Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.
Methods
This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control.
Results
Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P < .05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI, 1.30-4.80). Patients from the personalized arm were controlled in a shorter period of time (P = .01).
Conclusion
Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Hospital Municipal de Badalona, Badalona 08911, Spain.
- Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona 08916, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII), Barcelona 28029, Spain.
- Department of Endocrinology and Nutrition, La Princesa University Hospital, Madrid 28006, Spain.
- Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona 08916, Spain.
- Department of Endocrinology and Nutrition, Vall Hebron University Hospital, Barcelona 08035, Spain.
ORCID-Profile: Montserrat Marques-Pamies, Joan Gil, Betina Biagetti, Marta Araujo-Castro, Manel Puig-Domingo
Förderung
- Instituto de Salud Carlos III
- European Union-ERDF
Zitieren
APA
Marques-Pamies, M., Gil, J., Sampedro-Nuñez, M., Valassi, E., Biagetti, B., Giménez-Palop, O., Hernández, M., Martínez, S., Carrato, C., Villar-Taibo, R., Araujo-Castro, M., Blanco, C., Simón-Muela, I., Simó-Servat, A., Xifra, G., Vázquez, F., Pavón, I., Rosado, J. A., García-Centeno, R., …, & Puig-Domingo, M. (2024). Personalized Medicine in Acromegaly: The ACROFAST Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae444
Vancouver
Marques-Pamies M, Gil J, Sampedro-Nuñez M, Valassi E, Biagetti B, Giménez-Palop O, et al. Personalized Medicine in Acromegaly: The ACROFAST Study. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae444
BibTeX
@article{MarquesPamies2024,
author = {Marques-Pamies, Montserrat and Gil, Joan and Sampedro-Nuñez, Miguel and Valassi, Elena and Biagetti, Betina and Giménez-Palop, Olga and Hernández, Marta and Martínez, Silvia and Carrato, Cristina and Villar-Taibo, Rocío and Araujo-Castro, Marta and Blanco, Concepción and Simón-Muela, Inmaculada and Simó-Servat, Andreu and Xifra, Gemma and Vázquez, Federico and Pavón, Isabel and Rosado, José Antonio and García-Centeno, Rogelio and Zavala, Roxana and Hanzu, Felicia Alexandra and Mora, Mireia and Aulinas, Anna and Vilarrasa, Nuria and Librizzi, Soledad and Calatayud, María and de Miguel, Paz and Alvarez-Escola, Cristina and Picó, Antonio and Salinas, Isabel and Fajardo-Montañana, Carmen and Cámara, Rosa and Bernabéu, Ignacio and Jordà, Mireia and Webb, Susan M and Marazuela, Mónica and Puig-Domingo, Manel},
title = {Personalized Medicine in Acromegaly: The ACROFAST Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae444}
}
EUVIMED